title: Effects of tetrazanbigen on the protein expression in human hepatocellular carcinoma cell line QGY-7701.
abstract: Tetrazanbigen (TNBG) is a novel synthetic antitumor drug with significant antitumor effects on common solid tumors in vitro and in vivo. It may lead to death of cancer cells through a tumor-associated lipoidosis mechanism, and result in lipid droplets (LDs) accumulation at the cytoplasm. In this study, the effects of TNBG on protein expression in human hepatocellular carcinoma cell line QGY-7701 were studied for elucidating its antitumor mechanism. The proteins extracted from TNBG-treated human hepatocellular carcinoma cell line QGY-7701 were analyzed and compared with control cells by two-dimensional gel electrophoresis. The differential proteins were identified by matrix-associated laser desorption ionization time-of-flight mass (MALDI-TOF-MS) spectrometry. Two proteins of interest, the levels of which were significantly increased in TNBG-treated cells, were further characterized by Western blot analysis. The results showed a total of 846+/-23 spots in control cells and 853+/-30 spots in TNBG-treated cells. Twenty-six up-regulated or down-regulated proteins were found by analyzing differential proteomic 2-DE map. Eleven of them were identified by mass spectrometry. They were protein disulfide-isomerase precursor, 94 kD glucose-regulated protein, heat shock protein (HSP) 90-alpha, ATP-citrate lyase, HMG-CoA reductase, glucose-6-phosphate 1-dehydrogenase, very-long-chain specific acyl-CoA dehydrogenase, squalene synthetase, sterol regulatory element-binding protein 1, fructose-bisphosphate aldolase A, and peroxiredoxin-1. These up-regulated or down-regulated proteins are mostly related to lipid metabolism. The TNBG antitumor mechanism is probably to influence tumor lipid metabolism, resulting in accumulation of LDs in tumor cells.
authors.affiliation: Department of Medicinal Chemistry, Research Laboratory of Pharmaceutical Chemistry and Biomaterials, Chongqing Engineering Research Center of Drugs, School of Pharmacy, Chongqing, China. yonghuayuancq@163.com
authors.forename: Yonghua
authors.initials: Y
authors.lastname: Yuan
authors.forename: Wei
authors.initials: W
authors.lastname: Li
authors.forename: Longjiang
authors.initials: L
authors.lastname: Li
authors.forename: Xiaolan
authors.initials: X
authors.lastname: Yang
authors.forename: Rong
authors.initials: R
authors.lastname: Gu
authors.forename: Huabo
authors.initials: H
authors.lastname: Liu
authors.forename: Kaishun
authors.initials: K
authors.lastname: Huang
authors.forename: Yu
authors.initials: Y
authors.lastname: Yu
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology*; D001391:Azo Compounds / Q000494:pharmacology*; D006528:Carcinoma, Hepatocellular / Q000473:pathology*; D045744:Cell Line, Tumor; D006067:Gonanes / Q000494:pharmacology*; D006801:Humans; D008113:Liver Neoplasms / Q000473:pathology*; D011506:Proteins / Q000378:metabolism*; D020543:Proteome
chemical_list: D000970:Antineoplastic Agents; D001391:Azo Compounds; D006067:Gonanes; D011506:Proteins; D020543:Proteome; C552897:tetrazanbigen